1-amino-4-({3-[(4-chloro-6-{[(3 or 4)-sulfophenyl]amino}-1,3,5-triazin-2-yl)amino]-2,4,6-trimethyl-5-sulfophenyl}amino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid, lithium sodium salts

Acute Toxicity: dermal

Administrative data

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1989-06-02

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

guideline study with acceptable restrictions

Justification for type of information:

The main structure of the read-across substance is the same of the CJ304, only the salt form is different. However, this difference does not influence the toxicity of the CJ304. CJ304 contains Li/Na salt form and the read-across substances contains only Na salt. This will not lead to difference on the toxicity results.

Data source

Reference

Reference Type:

other company data

Title:

Unnamed

Year:

1989

Report date:

1989

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

EU Method B.3 (Acute Toxicity (Dermal))

Test guideline 2

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Version / remarks:

1981

GLP compliance:

yes

Limit test:

yes

Test material

Test material information

Constituent 1

Reference substance name:

Reaction products of 3-Pyridinemethanesulfonic acid, 5-[[5-[[4-chloro-6-[(4-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]azo]-1-ethyl-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, trisodium salt and 3-Pyridinemethanesulfonic acid, 5-[[5-[[4-chloro-6-[(3-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]azo]-1-ethyl-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, trisodium salt and lithium chloride

EC Number:

942-795-5

Molecular formula:

Not applicable; this UVCB substance contains: C24H20ClN8O11S3.xLi.yNa, (x + y) = 3; 0 < (x,y) < 3 with 748.9 < MW < 797.0 g/mol (UVCB substance), C24H21N8O12S3.xLi.yNa, (x + y) = 3; 0 < (x,y) < 3 with 730.4 < MW < 778.6 g/mol (UVCB substance), C18H15Cl2N7O8S2.xLi.yNa, (x + y) = 2; 0 < (x,y) < 2 with 606.2 < MW < 638.3 g/mol (UVCB substance), C21H17N8O9S3.xLi.yNa, (x + y) = 3; 0 < (x,y) < 3 with 642.4 < MW < 690.5 g/mol (UVCB substance), C30H25N9O14S4.xLi.yNa, (x + y) = 4; 0 < (x,y) < 4 with 891.5 < MW < 955.7 g/mol (UVCB substnace), and traces of NaCl and Na2SO4.

IUPAC Name:

Reaction products of 3-Pyridinemethanesulfonic acid, 5-[[5-[[4-chloro-6-[(4-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]azo]-1-ethyl-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, trisodium salt and 3-Pyridinemethanesulfonic acid, 5-[[5-[[4-chloro-6-[(3-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]azo]-1-ethyl-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, trisodium salt and lithium chloride

Test material form:

solid: particulate/powder

Test animals

Species:

rat

Strain:

other: Wistar KFM-Han. SPF

Administration / exposure

Type of coverage:

occlusive

Vehicle:

other: Dest. Wasser + 4 % CMC-Na-Salz

Duration of exposure:

24h

Doses:

Male: 2000 mg/kg bw; Number of animals: 5; Number of deaths: 0
Female: 2000 mg/kg bw; Number of animals: 5; Number of deaths: 0

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Clinical signs:

other:

Other findings:

Colouration of the skin surface.
In addition, the female rats exhibited erythema, scaling and a weight loss during the observation period. All of the above-mentioned symptoms disappeared at the end of the observation period.

Applicant's summary and conclusion

Interpretation of results:

GHS criteria not met

Conclusions:

No death was observed after the application. Therefore, the test substance is not classified for acute dermal toxicity.